• Change from baseline in the O'Leary-Sant Interstitial Cystitis Symptom Index (ICSI) score. [ Time Frame: 12 WEEKS ] [ Designated as safety issue: No ]
• Change from baseline in worst daily pain severity score as measured by an 11-point Numerical Rating Scale (NRS). [ Time Frame: 12 WEEKS ] [ Designated as safety issue: No ]

• Micturition Diary Variables including frequency, urgency, nocturnal frequency, incontinence episodes. [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
• ICSI at other time points [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
• Interstitial Cystitis Problem Index (ICPI) [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
• Pelvic pain Urgency Frequency score (PUF) [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
• Epworth Sleepiness Scale (ESS) [ Time Frame: 12 Weeks ] [ Designated as safety issue: Yes ]
• Columbia-Suicide Severity Rating Scale (C-SSRS) [ Time Frame: 15 Weeks ] [ Designated as safety issue: Yes ]
• Adverse events [ Time Frame: 15 Weeks ] [ Designated as safety issue: Yes ]
• Physical examination [ Time Frame: 14 Weeks ] [ Designated as safety issue: Yes ]
• Vital signs and weight [ Time Frame: 15 Weeks ] [ Designated as safety issue: Yes ]
• ECG [ Time Frame: 14 Weeks ] [ Designated as safety issue: Yes ]
• Residual urine volume measurement [ Time Frame: 14 Weeks ] [ Designated as safety issue: Yes ]
• Global Response assessment (GRA) [ Time Frame: 12 Weeks ] [ Designated as safety issue: No ]
• Patient Reported Treatment Impact (PRTI) [ Time Frame: 12 Weeks ] [ Designated as safety issue: No ]
• Treatment failures [ Time Frame: 12 Weeks ] [ Designated as safety issue: No ]
• Average and worst daily pain score at other time points as measured by an 11-point NRS. [ Time Frame: 12 Weeks ] [ Designated as safety issue: No ]
• Sleep disturbance and sexual activity pain. [ Time Frame: 12 Weeks ] [ Designated as safety issue: No ]
• Clinical laboratory tests [ Time Frame: 14 Weeks ] [ Designated as safety issue: Yes ]

• Micturition Diary Variables including frequency, urgency, nocturnal frequency, incontinence episodes. [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
• ICSI at other time points, Interstitial Cytstitis Problem Index (ICPI), and Pelvic pain Urgency Frequency score (PUF) [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
• Physical examination, vital signs and weight, ECG, residual urine volume measurement, Clinical laboratory tests • Epworth Sleepiness Scale (ESS). • Columbia-Suicide Severity Rating Scale (C-SSRS). • Adverse events [ Time Frame: 13 weeks ] [ Designated as safety issue: Yes ]
• Average and worst daily pain score at other time points as measured by an 11-point NRS. Sleep disturbance and sexual activity pain. [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
• Global Response assessment (GRA), Patient Reported Treatment Impact (PRTI), and treatment failures [ Time Frame: 12 Weeks ] [ Designated as safety issue: No ]

The purpose of this study is to determine whether PD 0299685 is effective in the treatment of symptoms associated with interstitial cystitis/painful bladder syndrome, such as pain, urinary urgency and frequency. At the same time assess the drug's safety and tolerability.

• Interstitial Cystitis
• Painful Bladder Syndrome

• Drug: PD 0299685 at 15mg BID
• Drug: PD 0299685 at 30mg BID
• Drug: placebo for PD 0299685

Inclusion Criteria:

• Men and women over 18 years of age with moderate to severe interstitial cystitis defined by pain score.
• Women must not be pregnant or lactating, They may be post-menopausal, surgically sterilized or using an appropriate method of contraception.

Exclusion Criteria:

• History of interstitial cystitis less than 6 months
• History of current or recurrent urinary tract infections, or genitourinary cancer
• Any previous urinary diversion procedure with or without bladder removal, bladder augmentation
• Use of certain drugs given into the bladder up to 1 month prior to study entry